EDGAR Filing Documents for 0001193125-16-751762

Form SC 13D - General statement of acquisition of beneficial ownership:

SEC Accession No. 0001193125-16-751762

Filing Date

2016-10-28

Accepted

2016-10-28 16:53:32

Documents

Group Members

BAYER AG

Document Format Files

Seq	Description	Document	Type	Size
1	SC 13D	d461269dsc13d.htm	SC 13D	49785
2	EX-99.A	d461269dex99a.htm	EX-99.A	4426
3	EX-99.B	d461269dex99b.htm	EX-99.B	12094
4	EX-99.E	d461269dex99e.htm	EX-99.E	56490
5	EX-99.F	d461269dex99f.htm	EX-99.F	23148
6	GRAPHIC	g461269dsp01.jpg	GRAPHIC	11069
	Complete submission text file	0001193125-16-751762.txt		162823

Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139

Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 6173154600

CRISPR Therapeutics AG (Subject) CIK: 0001674416 (see all company filings)

IRS No.: 473173478
Type: SC 13D | Act: 34 | File No.: 005-89674 | Film No.: 161959248
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O CRISPR THERAPEUTICS AG 200 SIDNEY STREET CAMBRIDGE MA 02139

Business Address C/O CRISPR THERAPEUTICS AG 200 SIDNEY STREET CAMBRIDGE MA 02139 617-315-4600

Bayer Global Investments B.V. (Filed by) CIK: 0001685417 (see all company filings)

IRS No.: 000000000 | State of Incorp.: XX | Fiscal Year End: 1231
Type: SC 13D